NASDAQ:FIXX - Homology Medicines Stock Price, Forecast & News

Homology Medicines trades on the NASDAQ under the ticker symbol "FIXX."

Homology Medicines Inc (NASDAQ:FIXX) announced its earnings results on Thursday, August, 8th. The company reported ($0.61) earnings per share for the quarter, missing analysts' consensus estimates of ($0.55) by $0.06. The company had revenue of $0.39 million for the quarter, compared to the consensus estimate of $1 million. Homology Medicines had a negative net margin of 4,740.81% and a negative return on equity of 43.33%. View Homology Medicines' Earnings History.

Homology Medicines is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Homology Medicines.

7 brokerages have issued 12 month price objectives for Homology Medicines' stock. Their forecasts range from $29.00 to $37.00. On average, they expect Homology Medicines' stock price to reach $33.20 in the next year. This suggests a possible upside of 106.7% from the stock's current price. View Analyst Price Targets for Homology Medicines.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Homology Medicines in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Homology Medicines.

News coverage about FIXX stock has trended somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Homology Medicines earned a news impact score of 2.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Homology Medicines.

Homology Medicines saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 3,510,000 shares, an increase of 15.1% from the January 15th total of 3,050,000 shares. Based on an average trading volume of 352,500 shares, the short-interest ratio is presently 10.0 days. Approximately 11.6% of the company's stock are short sold. View Homology Medicines' Current Options Chain.

Some companies that are related to Homology Medicines include Taro Pharmaceutical Industries (TARO), ChemoCentryx (CCXI), Apellis Pharmaceuticals (APLS), Uniqure (QURE), Amicus Therapeutics (FOLD), Arena Pharmaceuticals (ARNA), ArQule (ARQL), Insmed (INSM), Biohaven Pharmaceutical (BHVN), Principia Biopharma (PRNB), Synthorx (THOR), Ra Pharmaceuticals (RARX), Aurinia Pharmaceuticals (AUPH), Forty Seven (FTSV) and Prestige Consumer Healthcare (PBH).

Based on aggregate information from My MarketBeat watchlists, some companies that other Homology Medicines investors own include InterDigital Wireless (IDCC), Bank of Hawaii (BOH), Editas Medicine (EDIT), Heron Therapeutics (HRTX), Inovio Pharmaceuticals (INO), Pfizer (PFE), Stag Industrial (STAG), Gilead Sciences (GILD), Nektar Therapeutics (NKTR) and Novavax (NVAX).

(FIXX) raised $100 million in an IPO on Wednesday, March 28th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Evercore ISI acted as the underwriters for the IPO and BTIG was co-manager.

Homology Medicines' stock is owned by many different of institutional and retail investors. Top institutional investors include 5AM Venture Management LLC (12.57%), FMR LLC (4.92%), State Street Corp (1.86%), Geode Capital Management LLC (0.81%), Victory Capital Management Inc. (0.81%) and Victory Capital Management Inc. (0.80%). Company insiders that own Homology Medicines stock include Albert Seymour, Arthur Tzianabos, James E Flynn, Kush Parmar, Siyamak Rasty, Timothy P Kelly, Ventures Iv LP 5Am, Vida Ventures, Llc and W Bradford Smith. View Institutional Ownership Trends for Homology Medicines.

FIXX stock was sold by a variety of institutional investors in the last quarter, including Credit Suisse AG, Sofinnova Investments Inc., UBS Group AG, Victory Capital Management Inc., State Street Corp, Sectoral Asset Management Inc, Victory Capital Management Inc. and Citigroup Inc.. Company insiders that have sold Homology Medicines company stock in the last year include Albert Seymour, Arthur Tzianabos, James E Flynn, Kush Parmar, Siyamak Rasty, Timothy P Kelly and W Bradford Smith. View Insider Buying and Selling for Homology Medicines.

FIXX stock was bought by a variety of institutional investors in the last quarter, including 5AM Venture Management LLC, FMR LLC, California Public Employees Retirement System, Amia Capital LLP, Virtus ETF Advisers LLC, Geode Capital Management LLC, Goldman Sachs Group Inc. and Alpine Global Management LLC. Company insiders that have bought Homology Medicines stock in the last two years include James E Flynn and Vida Ventures, Llc. View Insider Buying and Selling for Homology Medicines.

Shares of FIXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of FIXX stock can currently be purchased for approximately $16.06.

Homology Medicines has a market capitalization of $707.20 million and generates $3.68 million in revenue each year. The company earns $-57,220,000.00 in net income (profit) each year or ($2.00) on an earnings per share basis. Homology Medicines employs 124 workers across the globe.View Additional Information About Homology Medicines.

The official website for Homology Medicines is http://www.homologymedicines.com/.

Homology Medicines' mailing address is ONE PATRIOTS PARK, BEDFORD MA, 01730. The company can be reached via phone at 781-301-7277.